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Abstract
Background: Urokinase-type Plasminogen Activator (uPA), a serine protease, plays a pivotal role
in human breast cancer metastasis by mediating the degradation of extracellular matrix proteins
and promoting cell motility. In more advanced breast cancers, uPA activity is significantly up
regulated and serves as a prognostic indicator of poor patient outcome. Classically, regulation of
uPA activity, especially in breast cancers, is thought to be mediated by Type 1 Plasminogen
Activator Inhibitor (PAI-1). However, we have recently found that a lesser known natural inhibitor
of uPA, Protease Nexin 1 (PN-1), is expressed in normal human mammary tissue. Based on this
observation, we investigated if PN-1 is also expressed in human breast cancers where it may
contribute to the regulation of uPA and participate in the development of a metastatic phenotype.
Results: Using quantitative real-time PCR analysis, we measured PN-1 mRNA expression in
tissues obtained from 26 human breast tumor biopsies and compared these values with those
obtained from 10 normal breast tissue samples. Since both PAI-1 and uPA expression levels are
known to be elevated in metastatic breast cancer, we also measured their levels in our 26 tumor
samples for direct comparison with PN-1 expression. We found that PN-1 expression was elevated
over that found in normal mammary tissue; an increase of 1.5- to 3.5-fold in 21 of 26 human breast
tumors examined. As anticipated, both PAI-1 and uPA mRNA levels were significantly higher in the
majority of breast tumors; 19 of 26 tumors for PAI-1 and 22 of 26 tumors for uPA. A quantile box
plot of these data demonstrates that the elevated PN-1 expression in breast tumor tissues directly
correlates with the increased expression levels found for PAI-1 and uPA.
Conclusion: The fact that PN-1 expression is elevated in human breast cancer, and that its
increased expression is directly correlated with increases measured for PAI-1 and uPA, suggests
that PN-1 may contribute to the regulation of uPA-mediate tumor cell motility and metastatic
spread.
Background
An important characteristic of highly invasive tumor cells
is an elevated capacity to degrade the surrounding extra-
cellular matrix (ECM). To achieve this elevated degrada-
tive capacity, tumor cells express a variety of proteases to
digest ECM proteins that typically encapsulate growing,
Published: 31 May 2006
Cancer Cell International 2006, 6:16 doi:10.1186/1475-2867-6-16
Received: 13 February 2006
Accepted: 31 May 2006
This article is available from: http://www.cancerci.com/content/6/1/16
© 2006 Candia et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Cancer Cell International 2006, 6:16 http://www.cancerci.com/content/6/1/16
Page 2 of 7
(page number not for citation purposes)
benign tumors [1,2]. It is now well established that pro-
teins of the plasminogen activation (PA) system are ele-
vated in breast cancer and serve as the primary functional
players in ECM degradation [3,4]. Expression of one
member of the PA system, the serine protease urokinase
(uPA), is significantly upregulated in tumor cells and cat-
alyzes the conversion of extracellular plasminogen to
plasmin [5]. Plasmin is a broad-spectrum protease that
cleaves many ECM proteins, as well as activates certain
matrix metalloproteinases [6]. This proteolytic cascade
enables highly migratory tumor cells to efficiently degrade
their surrounding matrices, exit the primary site of tumor
growth and colonize distant secondary sites [7]. In addi-
tion to its protease activity which augments breast tumor
cell motility, high expression levels of uPA is also a well-
established prognostic indicator of poor patient outcome
during the course of breast cancer [8,9].
Regulation of extracellular uPA activity is known to occur
through the inhibitory properties of type I plasminogen
activator inhibitor (PAI-1), a serine protease inhibitor
(SERPIN) that is synthesized and secreted often by the
same cells that secrete uPA [10]. Because of the close func-
tional relationship between uPA proteolytic activity and
PAI-1 inhibitory function, it is thought that a well-con-
trolled balance of uPA and PAI-1 dictates the extent of cell
motility. Protease Nexin-1 (PN-1), another member of the
SERPIN family [11], is highly expressed by stromal cells
[12] and a potent inhibitor of uPA [10,13]. Interestingly,
although PN-1 activity has been extensively studied
within the context of neural development, few studies
have been reported examining its expression in cancerous
tissues and its potential role in cancer progression. PN-1 is
expressed by astrocytes and glial cells [14], as well as neu-
roblastoma cells [15] where it is thought to promote neu-
ronal cell survival [16] and modulate neurite outgrowth
[17]. In addition, PN-1 inhibits thrombin-stimulated cell
division [18], migration of cerebrellar granular cells [19],
and uPA-dependent ECM degradation [20]. Thus, based
on findings in other cell types, we hypothesize that PN-1
may contribute to tumor cell motility in advanced stage
breast cancer by playing a role in the regulation of uPA
activity. To address this hypothesis, we examined the
expression of PN-1 in advanced stage human breast can-
cer tissues to determine if its expression is altered when
compared to normal mammary tissue and to directly
compare its expression level to those of PAI-1 and uPA. To
accomplish this goal, we used quantitative real-time
reverse transcription-PCR (QRT-PCR) to measure PN-1,
PAI-1 and uPA expression levels within a set of breast
tumor and normal breast tissue samples.
Materials and methods
Breast tissue samples
Frozen breast tumor specimens from anonymous patients
(n = 26) were obtained from the University of New Mex-
ico Cancer Research and Treatment Center Solid Tumor
Facility, Albuquerque, New Mexico. In 25 out of 26 cases,
tumor grade, tumor size, lymph node status, and the frac-
tion of cells in S phase (based on flow cytometry cell cycle
analysis) were included within the clinical history pro-
vided with each specimen. Anonymous normal breast
mRNA (n = 10) originating from female patients where
cause of death was unrelated to cancer, were purchased
from Ambion (Austin, TX). The normal, control samples
were supplied as two equal pools by the company.
Cell culture
MCF-7 human mammary epithelial cells, were provided
by Dr. Steven Abcouwer, Hershey Medical Center, Her-
shey, Pennsylvania. MDA-MB-231 metastatic human
mammary epithelial cells were obtained from American
Type Culture Collection (Rockland, MD). Both cell lines
were propagated in Dulbecco modified Eagle's medium
(DMEM, Life Technologies/Invitrogen, Carlsbad, CA)
supplemented with 10% fetal calf serum (Irvine Scientific,
Santa Ana, CA), 0.1 mM non-essential amino acids, 1 mM
sodium pyruvate, 0.01 mg/ml bovine insulin, and 100 U/
ml penicillin G. Cells were cultured at 37°C with 5% CO2
and passaged once a week.
Preparation of tissue sections and RNA isolation
Serial frozen sections of breast samples, 10 µm in width,
were mounted on Colorfrost slides (VWR, West Chester,
PA) and stored at -70°C. Specimens were stained with
hematoxylin/eosin and examined by a board-certified sur-
gical pathologist, who assigned a histopathologic grade to
the tumor and analyzed the normal tissue. Total RNA
from cultured cells and frozen tumor tissue was isolated
using silica-based spin-column extraction kits (RNeasy/
DNeasy mini kits, Qiagen, Valencia, CA) according to the
manufacturer's protocol. Total RNA was treated with
RNase-free DNase I (Ambion, Austin, TX) to eliminate
contaminating DNA. RNA integrity was evaluated by aga-
rose gel electrophoresis.
Quantitative real-time RT-PCR
cDNA was synthesized by random decamer-primed
reverse transcription of RNA (1 µg) using a TaqMan®
Reverse Transcription kit (Applied Biosystems, Foster
City, CA) according to the manufacturer's standard proto-
col. Negative controls contained RNase-free water substi-
tuted for reverse transcriptase. The mRNA levels of PN-1,
PAI-1, uPA and TATA-binding protein (TBP) were meas-
ured in breast specimens, the MCF-7 mammary epithelial
cell line, and the MDA-MB-231 metastatic mammary epi-
thelial cell line using the ABgene Absolute SYBR GreenCancer Cell International 2006, 6:16 http://www.cancerci.com/content/6/1/16
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QRT-PCR assay (Fisher Scientific, Hampton, NH). PN-1
primers were selected to amplify an 81 bp sequence span-
ning the intron located between exons 2 and 3. Primer
sequences used for PN-1 were 5'-GAAGCAGCTCGCCAT-
GGT-3' (forward), 5'-AGACGATGGCCTTGTTGATC-3'
(reverse). TBP primer sequences used were 5'-CACGAAC-
CACGGCACTGATT-3' (forward), 5'-TTTTCTTGCT-
GCCAGTCTGGAC-3' (reverse). Primer sequences used for
PAI-1 were 5'-TGCTGGTGAATGCCCTCTACT-3' (for-
ward), 5'-CGG TCA TTC CCA GGT TCT CTA-3' (reverse).
uPA primer sequences used were 5'-CAC GCA AGG GGA
GAT GAA-3' (forward), 5'-CA GCA TTT TGG TGG TGA
CTT-3' (reverse) [21]. Final concentration of PN-1, PAI-1
and uPA primers used for amplification was 600 nmol/L
forward, 600 nmol/L reverse; 600 nmol/L forward, 900
nmol/L reverse was used for TBP primers. Amplification
of PN-1, PAI-1, uPA and TBP cDNA was performed using
the MiniOpticon Real-Time PCR Detection System (Bio-
rad, Hercules, CA). The cycling parameters used were as
follows: 1 cycle, 95°C for 10 min; 50 cycles, 95°C for 15
sec and 60°C for 1 min; 1 cycle, 40°C for 3 min. The PN-
1, PAI-1 and uPA mRNA levels were normalized to TBP
mRNA levels using the Comparative CT method and are
reported in the figures as fold difference compared to lev-
els found in normal mammary tissue. Melting curve anal-
yses were performed for all amplifications to verify that
only single products were generated from the reactions.
Amplicons were sequenced to verify authentic PN-1. The
cDNA for human PN-1 was obtained from the I.M.A.G.E.
Consortium (ID: 4824856; Genbank: BC042628; Gen-
bank: BC042628).
Results
Quantitation of PN-1 expression in human breast tumors
For QRT-PCR analysis, we designed primers to amplify an
81 bp sequence of PN-1 spanning the splice junction
between exons 2 and 3. Spanning a splice junction
ensures that amplified products are derived solely from
mRNA and not from genomic DNA that might remain in
our preparation. In order to test the specificity of these
novel primers, we amplified the 81 bp PN-I sequence by
straight RT-PCR using RNA purified from a normal
human fibroblast cell line (HuFb) and compared the
product to that obtained from amplification using the
human PN-1 cDNA. We chose to use human fibroblasts
since they synthesize and secrete active PN-1 at levels cor-
responding to ~1% of all secreted proteins [22,23]. As
anticipated, we found that our newly designed primers
amplified only the expected 81 bp sequence (data not
shown).
To quantify PN-1 expression in human breast cancers, we
obtained 26 samples of breast tumor tissue, purified RNA
and generated cDNA from this material. The cDNA were
then analyzed by quantitative PCR and the results were
compared directly to quantitative PCR values obtained
using cDNA generated from normal human mammary tis-
sue. We found that PN-1 expression was elevated over that
found in normal mammary tissue; an increase of 1.5- to
3.5-fold in 21 of 26 human breast tumors examined (Fig.
1A). Since both PAI-1 [24-26] and uPA [24,26] expression
levels are known to be elevated in metastatic breast cancer,
we measured their levels in our 26 tumor samples for
direct comparison with PN-1 expression. As anticipated,
both PAI-1 (Fig. 1B) and uPA (Fig. 1C) mRNA levels were
significantly higher in the majority of breast tumors; 19 of
26 tumors for PAI-1 and 22 of 26 tumors for uPA. A quan-
tile box plot of the data shown in Figure 1 permits a direct
comparison of expression levels for PN-1, PAI-1 and uPA
(Fig. 2). These data clearly show that PN-1 expression is
elevated in the majority of human breast cancers exam-
ined and that this elevated expression directly correlates
with the expected higher expression levels found for PAI-
1 and uPA. Since the majority of our tumor samples rep-
resent advanced stage, grade 2 and 3 breast cancers, we are
unable to determine at this time if PN-1 expression levels
correlate with tumor grade, lymph node status or patient
reoccurrence.
PN-1 expression in MCF-7 and MDA-MB-231 breast 
cancer cells
We plan to characterize the mechanism responsible for
increased expression of PN-1 in breast cancer and deter-
mine its functional role in breast cancer metastasis. To
accomplish this goal, we will require a cultured model sys-
tem for accurate, controlled assessment of PN-1 promoter
status, transcription factor requirements, and tumor cell
invasive capacity. MCF-7 and MDA-MB-231 cells are well
established cultured lines used extensively to study molec-
ular details of breast cancer progression [27]. Hormone-
responsive MCF-7 cells have a low invasive capacity and
represent earlier stages of breast cancer, while hormone-
independent MDA-MB-231 cells are highly invasive and
represent more advanced stage breast cancer. To deter-
mine if these cell models will be useful for examining PN-
1 function in breast cancer, we performed QRT-PCR anal-
ysis to identify if PN-1 expression is disregulated in a com-
parable manner to that seen in human breast cancer
tissues. We found that MDA-MB-231 cells express 3.5-fold
greater levels of PN-1 than MCF-7 cells (Fig. 3). Moreover,
increased expression of PAI-1 and uPA were also found in
MDA-MB-231 cells as compared to MCF-7.
Discussion
Advanced stage breast cancer is accompanied by a dra-
matic increase in metastatic potential of epithelial-derived
tumor cells. The observed increase in tumor cell motility
is aided by increased expression and activity of uPA [4].
For effective tumor cell migration, the proteolytic activity
of uPA is thought to be balanced by the inhibitory activityCancer Cell International 2006, 6:16 http://www.cancerci.com/content/6/1/16
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PN-1, PAI-1 and uPA mRNA expression in human breast tumor tissues and normal human mammary tissue Figure 1
PN-1, PAI-1 and uPA mRNA expression in human breast tumor tissues and normal human mammary tissue. 
RNA was isolated from 26 breast tumors (T1–T26) and 10 normal breast samples. Normal samples were pooled into two 
equal groups (N1 and N2). mRNA levels for each gene were evaluated by QRT-PCR. Relative levels of PN-1, PAI-1 and uPA 
mRNA were normalized to TATA binding protein mRNA levels. Comparative CT method was used to calculate fold difference 
of PN-1 (A), PAI-1 (B) and uPA (C) expression in breast tumor tissue as compared to levels measured in normal breast tissue. 
The mean value of the two pooled normal samples was calculated and assigned a value of one in order to determine relative 
fold change of expression within the tumor samples. The standard deviation of the normal samples was 0.263. The box repre-
sents one standard deviation of the mean values obtained from normal mammary tissues.Cancer Cell International 2006, 6:16 http://www.cancerci.com/content/6/1/16
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of PAI-1 [28,29]. The cycling activities of proteolysis and
protease inhibition lead to sequential rounds of cell
detachment-reattachment, which in turn leads to an
increase in cell motility. Indeed, elevated expression levels
of both uPA and PAI-1 are characteristic of advanced stage
breast cancers [30]. Interestingly, although PN-1 is struc-
turally and functionally related to PAI-1, there have been
no studies to date investigating if PN-1 contributes to
breast cancer progression in a manner similar to that of
PAI-1. To address this gap in knowledge, we examined if
PN-1 expression is altered in human breast cancer by
quantitating levels of PN-1 expression in human tissue
samples obtained from tumor biopsies. In these same
samples, we also quantitated PAI-1 and uPA expression
levels for direct comparison to PN-1. Our findings indi-
cate that PN-1 expression is elevated in the majority of
human breast tumor tissues examined and that its expres-
sion levels are directly correlated with increases measured
for PAI-1 and uPA. We also found that the highly meta-
static, MDA-MB-231 breast cancer line expresses 3.5-fold
greater levels of PN-1 compared to the non-tumorgenic,
MCF-7 breast cancer cell line. This increase in PN-1 is also
correlated to increases seen for PAI-1 and uPA in MDA-
MB-231 cells. The elevated expression of all three genes is
consistent with our measurements in human breast tumor
samples. The significant differences in PN-1 expression
between non-tumorigenic MCF-7 cells and highly inva-
sive MDA-MB-231 cells should provide us with a good
basis for identifying the mechanism responsible for
altered PN-1 expression seen in breast tissues and allow us
to examine PN-1 function in the context of elevated PAI-1
and uPA levels. Taken together, these data indicate that
PN-1 expression is increased during breast cancer tumori-
genesis and may contribute, along with PAI-1, to uPA-
mediated tumor cell motility and a more advanced meta-
static phenotype.
Although studies in the literature investigating a role for
PN-1 in cancer progression are limited, our results com-
plement and extend data presented in a recent report by
Buchholz and colleagues [31]. Their study demonstrated
that a highly metastatic pancreatic cancer line overex-
pressed PN-1, while a less metastatic subclone showed lit-
tle PN-1 expression. The authors also noted that stable
PN-1 overexpression in the less metastatic subclone
greatly enhanced its local invasiveness in in vivo studies.
Our studies expand on these observations by demonstrat-
ing an increase in PN-1 expression in human breast cancer
tissues.
Quantitating expression of PAI-1 and uPA is of high prog-
nostic value for assessing breast cancer survival outcome
[24,25]. Numerous independent studies have shown that
patients with low levels of PAI-1 and uPA in their primary
tumor tissue have a significantly better survival rate than
Comparison of PN-1, PAI-1 and uPA mRNA expression lev- els in 26 breast tumor samples Figure 2
Comparison of PN-1, PAI-1 and uPA mRNA expres-
sion levels in 26 breast tumor samples. The box for 
each gene represents the interquartile range (25–75th per-
centile) and the line within this box is the median value. Bot-
tom and top bars of the whisker indicate the 10th and 90th 
percentiles, respectively. Outlier values are indicated (closed 
squares).
QRT-PCR analysis of PN-1, PAI-1 and uPA mRNA expres- sion in MCF-7 and MDA-MB-231 breast cancer cell lines Figure 3
QRT-PCR analysis of PN-1, PAI-1 and uPA mRNA 
expression in MCF-7 and MDA-MB-231 breast cancer 
cell lines. PN-1, PAI-1 and uPA message levels were quanti-
tated in MCF-7 and MDA-MB-231 cells by QRT-PCR. 
Expression levels for PN-1, PAI-1 and uPA were normalized 
to values obtained for TATA binding protein. CT values for 
each gene obtained from MCF-7 cells were averaged and 
assigned a value of one to assess relative fold increase in 
expression in MDA-MB-231 cells.Cancer Cell International 2006, 6:16 http://www.cancerci.com/content/6/1/16
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patients with high levels of either factor alone. Recently,
the prognostic value of PAI-1 and uPA has been verified
by a pooled analysis consisting of >8,000 breast cancer
patients [26]. In light of the overlapping protease specifi-
cities of PAI-1 and PN-1 [32], together with the estab-
lished role of PN-1 in neuronal cell regulation and
motility [33,34], we believe it is likely that PN-1 also plays
a role in breast cancer progression by contributing to
events necessary for increased tumor cell motility.
Increased expression of PN-1 by tumor cells may serve to
modulate their adhesiveness or motility [35]. Alterna-
tively, tumor cell activity may be influenced by tumor-
stromal tissue crosstalk [36]. The breast neoplastic stroma
contains a heterogeneous cell population composed of
fibroblasts, myofibroblasts, and endothelial cells, which
are all known to synthesize and secrete significant
amounts of PN-1 [37]. Although it remains to be deter-
mined the precise mechanism by which PN-1 contributes
to breast cancer tumor progression, the results of the
present study establish a rationale for further investigation
of PN-1 as a modulator of uPA activity in breast tumor cell
motility. Future studies will be focused on identifying
transcriptional and/or translational mechanisms control-
ling PN-1 expression by cancer cells and determining if
PN-1 serves as an independent prognostic indicator of
breast cancer staging by using a more widely defined sam-
ple of tumor tissues, including earlier stage cancers as well
as late-stage carcinomas. In addition, the use of laser cap-
ture dissection technology will confine our QRT-PCR
measurements to tumor tissue and eliminate contribu-
tions from surrounding normal mammary tissue that are
likely to occur when using surgical specimens.
Conclusion
We quantitated PN-1 expression in samples obtained
from biopsies of human breast tumors and from normal
mammary tissues by QRT-PCR analysis and compared
these results to those obtained for PAI-1 and uPA. Our
findings indicate that PN-1 expression is elevated in a
majority of human breast tumor tissues examined when
compared to normal human mammary tissue. In addi-
tion, the elevated PN-1 expression in tumor tissues
directly correlates with increased expression measured for
PAI-1 and uPA. We also found that the highly metastatic,
MDA-MB-231 breast cancer cell line expresses greater lev-
els of PN-1 compared to the non-tumorgenic, MCF-7
breast cancer cell line. Consistent with observations
obtained from tumor biopsies, PN-1 expression levels in
MDA-MB-231 directly correlate with increases found for
PAI-1 and uPA. These data indicate that PN-1 expression
is increased during breast cancer tumorigenesis and may
contribute, along with PAI-1, to uPA-mediated tumor cell
motility and a more advanced metastatic phenotype.
Abbreviations
uPA, urokinase-type plasminogen activator; PAI-1, plas-
minogen activator inhibitor; ECM, extracellular matrix;
PA, plasminogen activation; SERPIN, serine protease
inhibitor; PN-1, protease nexin-1.
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